akkermansia glp-1 complex Designs for Health launches probiotic GLP-1 Supplement, GLP-1 with Akkermansia

The new study is a step toward creating precision obesity tools to guide the use of a powerful, expensive class of medicines

Licensing (Marketing Authorisation): The MHRA has approved: Semaglutide (Wegovy) for adults with BMI 30 kg/m or BMI 27 kg/m with at least one weight-related comorbidity Liraglutide (Saxenda) with similar BMI criteria NHS Access (NICE Guidance): According to NICE guidance (TA664 for semaglutide), NHS-funded treatment is more restricted and typically available for adults with: BMI 35 kg/m with at least one weight-related comorbidity (such as hypertension, type 2 diabetes, dyslipidaemia, obstructive sleep apnoea, or cardiovascular disease) For individuals from Black, Asian, and minority ethnic backgrounds, lower BMI thresholds may apply, recognising that these populations face increased metabolic risk at lower BMI levels

Oxidative stress also affects ovarian cells supporting the oocyte

walking for 20 to 30 minutes after meals stimulates intestinal contractions without medication